U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2
Molecular Weight 160.2161
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOLAZOLINE

SMILES

c1ccc(cc1)CC2=NCCN2

InChI

InChIKey=JIVZKJJQOZQXQB-UHFFFAOYSA-N
InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C10H12N2
Molecular Weight 160.2161
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tolazoline, also known as priscoline, was used in treatment of persistent pulmonary hypertension of the newborn. But that prescription was discontinued. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance. The mechanisms of its therapeutic effects are not clear, but is known, that tolazoline is a non-selective competitive α-adrenergic receptor antagonist and it possesses histamine agonist activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PRISCOLINE

Approved Use

Unknown

Launch Date

-6.8774402E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.8 mg/L
3.2 mg single, intravenous
dose: 3.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOLAZOLINE blood
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.15 h
3.2 mg single, intravenous
dose: 3.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOLAZOLINE blood
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Other AEs: Erythema, Thrombocytopenia...
Other AEs:
Erythema (60%)
Thrombocytopenia (45%)
Hyponatremia (40%)
Gastric acid increased (36%)
Seizures (30%)
Hematuria (23%)
Hypotension (19%)
Oliguria (11%)
Abdominal distension (9%)
Activity motor exaggerated (6%)
Tracheal bleeding (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Oliguria 11%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hypotension 19%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hematuria 23%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Seizures 30%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Gastric acid increased 36%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Hyponatremia 40%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Thrombocytopenia 45%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Activity motor exaggerated 6%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Tracheal bleeding 6%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Erythema 60%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Abdominal distension 9%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, 36 weeks
n = 47
Health Status: unhealthy
Age Group: 36 weeks
Population Size: 47
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction.
1979 Feb
Hypochloremic metabolic alkalosis following tolazoline-induced gastric hypersecretion.
1980 Feb
Tolazoline and acute renal failure in the newborn.
1981 May 30
[Tolazoline and dopamine in the treatment of the persistent fetal circulation syndrome].
1983 Oct
[Renal disorders in the newborn infant].
1984 Jan-Feb
Bolus and continuous infusion of tolazoline in neonates with hypoxemia.
1986
Blood flow distribution and brain metabolism during tolazoline-induced hypotension in newborn dogs.
1990 Aug
Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient.
1996 May-Jun
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
1998 Apr 1
Endotracheal tolazoline: pharmacokinetics and pharmacodynamics in dogs.
1999 Sep
Reinnervation of the biceps brachii muscle following cotransplantation of fetal spinal cord and autologous peripheral nerve into the injured cervical spinal cord of the adult rat.
2001 Feb
[Indication for lung biopsy and usefulness of lung biopsy].
2001 Jun
[A case of Down syndrome with ventricular septal defect and hemodynamical Eisenmenger syndrome].
2001 May
Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline.
2001 Nov
Inhaled nitric oxide applications in paediatric practice.
2002 Jan
Use of azaperone and zuclopenthixol acetate to facilitate translocation of white-tailed deer (Odocoileus virginianus).
2002 Jun
[Aggression to the immature kidney].
2002 Mar-Apr
Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants.
2002 May
Is nebulised tolazoline an effective treatment for persistent pulmonary hypertension of the newborn?
2003 Jan
Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine.
2003 Jul
Octopaminergic modulation of synaptic transmission between an identified sensory afferent and flight motoneuron in the locust.
2003 Jul 14
Comparison of the vasodilating effect of nitroglycerin, verapamil, and tolazoline in hand angiography.
2003 Jun
Pharmacokinetics of xylazine, 2,6-dimethylaniline, and tolazoline in tissues from yearling cattle and milk from mature dairy cows after sedation with xylazine hydrochloride and reversal with tolazoline hydrochloride.
2003 Summer
A comparison of two intramuscular doses of xylazine-ketamine combination and tolazoline reversal in llamas.
2004 Apr
Clinically diagnosed nonocclusive mesenteric ischemia after cardiopulmonary bypass: retrospective study.
2004 Mar
Characterisation of some pharmacological effects of the venom from Vipera lebetina.
2004 Mar 15
Ergotamine-induced upper extremity ischemia: a case report.
2005 Apr-Jun
Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.
2006
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum.
2006 Jul
Reported medication use in the neonatal intensive care unit: data from a large national data set.
2006 Jun
Impaired cognition and attention in adults: pharmacological management strategies.
2007 Feb
A diazonium ion cascade from the nitrosation of tolazoline, an imidazoline-containing drug.
2008 Feb
Nucleoside and DNA adducts from N-nitrosotolazoline.
2008 Feb
N-nitrosotolazoline: decomposition studies of a typical N-nitrosoimidazoline.
2008 Feb
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline.
2008 May
Effect of vasoactive agents on the dermatopharmacokinetics and systemic disposition of model compounds, salicylate and FITC-dextran 4 kDa, following intracutaneous injection of the compounds.
2008 May 22
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
2008 Oct
Evaluation of intramuscular butorphanol, azaperone, and medetomidine and nasal oxygen insufflation for the chemical immobilization of white-tailed deer, Odocoileus virginianus.
2008 Sep
Butorphanol-azaperone-medetomidine for immobilization of captive white-tailed deer.
2009 Apr
A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators.
2009 Feb 1
The clinical outcomes of transcatheter microcoil embolization in patients with active lower gastrointestinal bleeding in the small bowel.
2009 Jul-Aug
Physiologic effects of nasal oxygen or medical air administered prior to and during carfentanil-xylazine anesthesia in North American elk (Cervus canadensis manitobensis).
2009 Mar
Accurate localization of life threatening colonic hemorrhage during nuclear medicine bleeding scan as an aid to selective angiography.
2009 May 27
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.
2010
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.
2010 Aug
Functional and pharmacological characterization of a beta-adrenergic-like octopamine receptor from the silkworm Bombyx mori.
2010 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Patents

Sample Use Guides

In Vivo Use Guide
An initial dose of 1 to 2 mg/kg, via scalp vein, followed by an infusion of 1 to 2 mg/kg per hour have usually resulted in significant increases in arterial oxygen. There is very little experience with infusions lasting beyond 36 to 48 hours. Response, if it occurs, can be expected within 30 minutes after the initial dose.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:25:20 UTC 2021
Edited
by admin
on Sat Jun 26 10:25:20 UTC 2021
Record UNII
CHH9H12AQ3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOLAZOLINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TOLAZOLINE [VANDF]
Common Name English
NSC-35110
Code English
TOLAZOLINE [INN]
Common Name English
TOLAZOLINE [MI]
Common Name English
TOLAZINE
Brand Name English
TOLAZOLINE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QM02AX02
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
WHO-VATC QV03AB94
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
WHO-ATC M02AX02
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
WHO-VATC QC04AB02
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
WHO-ATC C04AB02
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
Code System Code Type Description
WIKIPEDIA
TOLAZOLINE
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
EVMPD
SUB11148MIG
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
CAS
59-98-3
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
EPA CompTox
59-98-3
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
DRUG BANK
DB00797
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-448-9
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
MESH
D014043
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
MERCK INDEX
M10936
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C66608
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
IUPHAR
7310
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
INN
4213
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL770
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
FDA UNII
CHH9H12AQ3
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
PUBCHEM
5504
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
RXCUI
10634
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
2695
Created by admin on Sat Jun 26 10:25:20 UTC 2021 , Edited by admin on Sat Jun 26 10:25:20 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SHORT-ACTING
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY